| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 279, Issue 33, 34227-34239, August 13, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
||**
From the
Departments of Medicine, ||Biochemistry, **Pharmacology, and ¶Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia 23298 and the Department of Pediatrics, University of Texas M. D. Anderson Center, Houston, Texas 77030
Received for publication, March 1, 2004 , and in revised form, June 2, 2004.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Imatinib mesylate (STI-571, Gleevec, CGP57148B) is a 2-phenylamino pyrimidine that targets the ATP-binding site of the kinase domain of Abl (11). Imatinib mesylate is lethal to Bcr/Abl-positive cells in culture (12, 13). Moreover, this agent has proven highly effective in patients with chronic phase CML and, to a lesser extent, in patients with accelerated or blast phase disease (14, 15). Resistance to imatinib mesylate stems from BCR/ABL gene amplification, leading to overexpression of Bcr/Abl protein (16, 17), or point mutations in the BCR/ABL gene, resulting in a single amino acid substitution (e.g. Thr-315 
Ile or Glu-255 Lys or Glu-255 Val) within the ATP pocket of the Abl kinase domain known to be essential for imatinib mesylate binding (17, 18). In addition, mutations outside of the kinase domain that allosterically inhibit imatinib mesylate binding to the Bcr/Abl protein have now been described (19).
Recently, a putatively Bcr/Abl-independent form of imatinib mesylate resistance has been reported by several groups (20–22). Specifically, Bcr/Abl-positive CML cells cultured in the continuous presence of imatinib mesylate (20, 21), or obtained from certain CML patients who have progressed while receiving imatinib mesylate (22), display a decline in Bcr/Abl protein and/or mRNA levels and a corresponding increase in expression/activity of the Lyn and Hck kinase (21, 22). Lyn and Hck represent members of the Src tyrosine kinase family and have been implicated in the regulation of cell survival and proliferation, among numerous other functions (23, 24). Lyn exists in two isoforms, p56 and p53, derived from alternatively spliced mRNAs (25). The catalytic activity of Lyn is tightly regulated through tyrosine phosphorylation at the conserved Tyr-508 (26). Evidence derived from both murine and human model systems suggests that Lyn is a potentially important downstream target of Bcr/Abl (27); moreover, Lyn has been shown to be activated in Bcr/Abl-positive cells obtained from CML patients in blast crisis as well as in HL-60 human leukemia cells transfected with Bcr/Abl (28). Together, such findings raise the possibility that activation of Lyn can subserve the anti-apoptotic functions of Bcr/Abl, including conditions in which expression of Bcr/Abl is diminished, for whatever reason.
Although the role that Lyn plays in protecting cells from lethal stimuli has been examined in some detail (29), the functional relationship that exists between this Src kinase and Bcr/Abl remains to be fully elucidated. Moreover, no information exists concerning interactions hyperactivated Lyn might have with Bcl-2 family members. To address these issues, we have examined the molecular profile of human CML cells that have become resistant to imatinib mesylate in association with the loss of Bcr/Abl and activation of the Lyn kinase. Here we report that in such cells activation of Lyn is associated with a pronounced increase in the levels of the anti-apoptotic protein Bcl-2 and that disruption of Lyn activation through either pharmacologic or genetic strategies has a significant functional impact on Bcl-2 expression and resistance to mitochondria-dependent apoptosis. In addition, pharmacological or genetic disruption of Bcl-2 function increases the susceptibility of these resistant cells to lethality of imatinib mesylate or the topoisomerase II inhibitor VP-16. These findings may have implications for the development of new therapeutic strategies directed against leukemia cells exhibiting novel forms of imatinib mesylate resistance.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Imatinib mesylate (Gleevec, STI-571), provided by Dr. Elizabeth Buchdunger (Novartis Pharmaceuticals, Basel, Switzerland), was dissolved in Me2SO at a stock concentration of 50 mM, stored at –20 °C, and subsequently diluted with serum-free RPMI medium prior to use. 4-Amino-5-[4-chlorophenyl]-7-[t-butyl]pyrazolo[3,4-d]pyrimidine (PP2), a selective inhibitor of the Src family tyrosine kinases (31), 4-amino-7-phenylpyrazolo[3,4-d]pyrimidine (PP3), a negative control for PP2, and ethyl-2-amino-6-bromo-4-[1-cyano-2-ethoxy-2-oxoethyl]-4H-chromene-3-carboxylate (HA14-1), a cell-permeable and low molecular weight Bcl-2 inhibitory ligand (32, 33), were purchased from Calbiochem and Biomol (Plymouth Meeting, PA). cpm-1285 (a cell-permeable Bcl-2-binding peptide derived from the BH3 domain encompassing residues 140–165) and its negative control peptide cpm-1285mt (a mutant in which Leu-151 is replaced by Ala) (34) were provided by Calbiochem. Etoposide (VP-16), a topoisomerase II inhibitor, was obtained from Sigma. These agents were dissolved in Me2SO as a stock solution and stored at –80 °C. In all experiments, the final concentration of Me2SO did not exceed 0.1%.
Transient and Stable Transfection with cDNAs—cDNAs encoding full-length, kinase-defective (K275D, in which Asp is substituted for Lys-275 in the ATP-binding pocket), and constitutively active (Y508F, in which Tyr-508 is substituted in the conserved tail of the C terminus with Phe) Lyn were subcloned into pcDNA3 containing an HA tag (26). Bcl-2 cDNA (wild type) in pUSEamp was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). LAMA84 and K562 cells (1 x 106 per condition) were transiently transfected with three forms of Lyn cDNA (i.e. wild type, K275D, and Y508F) and Bcl-2 cDNA, respectively, using the Amaxa Nucleofector Device (program T-16) with Cell Line-specific Nucleofector Kit V (Amaxa GmbH, Cologne, Germany). Alternatively, K562 and LAMA84 cells were transfected with K275D and Y508F constructs as well as their empty vector counterparts (pcDNA3), respectively, and stably transfected clones were selected by limited dilution using G418.
Bcl-2 RNA Interference and Antisense Oligonucleotides—1 x 106 LAMA84 and LAMA-R cells were transfected with 2 µg of Bcl-2-annealed dsRNAi oligonucleotide (5'-GUACAUCCAUUAUAAGCUGTT-3'/3'-TTCAUGUAGGUAAUAUUCGAC-5', Orbigen, San Diego, CA) and SignalSilence Control siRNA (Cell Signaling, Beverly, MA), respectively, using the Amaxa Nucleofector Device (program T-16, Kit V). Alternatively, LAMA84 and LAMA-R cells were transfected with 5 µgof a Bcl-2 antisense oligonucleotide (5'-TCTCCCAGCGTGCGCCAT-3', G3139, Calbiochem) or a scrambled control oligonucleotide (5'-TACCGCGTGCGACCCTCT-3', G3622, Calbiochem) as described for transfection with dsRNAi. Transfection efficiency (>80% at 24 h post-transfection) was monitored by using fluorescein-labeled dsRNAi or antisense oligonucleotide and flow cytometric analysis. Bcl-2 protein levels were determined by Western blot analysis.
Apoptosis and Viability—The extent of apoptosis was evaluated by annexin V-FITC staining and flow cytometry. Briefly, 1 x 106 cells were stained with annexin V-FITC (Pharmingen) and 5 µg/ml propidium iodide (PI, Sigma) in 1x binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaOH, 2.5 mM CaCl2) for 15 min at room temperature in the dark. The samples were analyzed by flow cytometry within 1 h to determine the percentage of cells displaying annexin V+ (early apoptosis) or annexin V+/PI+ staining (late apoptosis). The ViaCount assay was performed to evaluate cell viability in the experiments involving transient transfection. 1 x 105 cells were stained with Guava ViaCount Reagent, and the percentage of viable cells was determined using a Guava Personal Cytometer (Gauva Technologies, Hayward, CA) as per the manufacturer's instructions. The ViaCount assay distinguishes between viable and nonviable cells, based on the differential permeability of DNA-binding dyes in the ViaCount Reagent, and was found to correlate closely with the results of annexin/PI staining.
Mitochondrial Membrane Potential (
m)—2 x 105 cells were stained with 40 nM 3,3-dihexyloxacarbocyanine (DiOC6; Molecular Probes Inc., Eugene, OR) in phosphate-buffered saline at 37 °C for 20 min and then analyzed by flow cytometry. The percentage of cells exhibiting decreased level of DiOC6 uptake, which reflects loss of m, was determined using FACScan from BD Biosciences.
Cell Growth and Survival (MTT Assay)—5 x 104 (in 100 µl volume)/well cells were seeded into 96-well plates and incubated with 20 µl of CellTiter 96® AQueous One Solution (Promega, Madison, WI) as per the manufacturer's instructions, and the absorbance at 490 nm was recorded using a 96-well plate reader (Molecular Devices, Sunnyvale, CA).
Western Blot—Whole-cell pellets were lysed in SDS sample buffer, and 30 µg of protein for each condition was subjected to Western blot analysis following the procedures described in detail previously (35). Where indicated, the blots were reprobed with antibodies against 
-actin (rabbit polyclonal, Transduction Laboratories, Lexington, KY) or 
-tubulin (mouse monoclonal, Calbiochem) to ensure equal loading and transfer of proteins. The following antibodies were used as primary antibodies: phospho-Bcr (Tyr-177) antibody (rabbit polyclonal, Cell Signaling), c-Abl antibody (mouse monoclonal, Santa Cruz Biotechnology, Santa Cruz, CA), STAT5 antibody (rabbit polyclonal, Santa Cruz Biotechnology), Bcl-xL antibody (rabbit polyclonal, Cell Signaling), anti-PARP (poly [ADP-ribose] polymerase, mouse monoclonal, Biomol), phospho-Lyn (Tyr-507) antibody (rabbit polyclonal, Cell Signaling), Lyn antibody (rabbit polyclonal, Cell Signaling), anti-human Bcl-2 oncoprotein (mouse monoclonal, Dako, Carpinteria, CA), Bax antibody (rabbit polyclonal, Santa Cruz Biotechnology), XIAP antibody (mouse monoclonal, Transduction Laboratories), phospho-CrkL (Tyr-207) antibody (rabbit polyclonal, Cell Signaling), CrkL (32H4) antibody (mouse monoclonal, Cell Signaling), phospho-Hck (Tyr-411) antibody (rabbit polyclonal, Santa Cruz Biotechnology), anti-Hck antibody (rabbit polyclonal, Upstate Biotechnology, Inc.), and HA probe (rabbit polyclonal, Santa Cruz Biotechnology). In some cases, the density of blots was quantified using FluoChem 8800 Imaging System (Alpha Innotech, San Leandro, CA) and VideoTesT-Master software (VideoTesT, Ltd., St. Petersburg, Russia).
Translocation of Bax, Cytochrome c, and AIF—4 x 106 cells were washed in phosphate-buffered saline and lysed by incubating for 30 s in lysis buffer (75 mM NaCl, 8 mM Na2HPO4, 1 mM NaH2PO4, 1 mM EDTA, and 350 µg/ml digitonin). After centrifuged at 12,000 x g for 1 min, the supernatant (cytosolic fraction) was collected in an equal volume of 2x sample buffer, and the pellet (mitochondria-rich fraction) was lysed by sonication in 1x SDS sample buffer. For both cytosolic and pellet fractions, the proteins were quantified, and 30 µg of protein per condition was separated by 15% SDS-PAGE and subjected to Western blot, as described above, using Bax antibody, cytochrome c antibody (mouse monoclonal, Santa Cruz Biotechnology), and AIF antibody (mouse monoclonal, Santa Cruz Biotechnology) as primary antibody.
RT-PCR—Total RNA was isolated from 1 x 106 cells using RNeasy mini kit (Qiagen, Valencia, CA) with QIAshredder spin column (Qiagen) as per the manufacturer's instructions. 1 µg per condition of total RNA was subjected to RT-PCR using One-step RT-PCR kit (Qiagen) and PTC-200 Peltier Thermal cycler (MJ Research, Reno, NV). The primers (forward, 5'-CGACTTCGCCGAGATGTCCAGGCAG-3'; reverse, 5'-GACCCACGGATAGACCCGGTGTTCA-3') were used for Bcl-2. RT-PCR was performed under the conditions as follows: reverse transcription at 50 °C for 30 min, initial PCR activation step at 95 °C for 15 min, three-step cycling (denaturing at 94 °C for 30 s, annealing at 55 °C for 30 s, and extension at 72 °C for 1 min) for 30 cycles, and final extension at 72 °C for 10 min. The reactions were run, in parallel, for actin as endogenous control. PCR products of Bcl-2 (388 bp) were analyzed in 2% agarose gel with ethidium bromide.
Real Time Quantitative RT-PCR—Total RNA was prepared as described above. The real time RT-PCR was performed on the ABI Prism 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) using the TaqMan One-step PCR Master Mix Reagents kit (P/N, 4309169). All the samples were tested in triplicate under the conditions recommended by the fabricant. The cycling conditions are as follows: 48 °C/30 min; 95 °C/10 min; and 40 cycles of 95 °C/15 s and 60 °C/1 min. The cycle threshold was determined to provide the optimal standard curve values (0.98 to 1.0). The probes (5'-CCTGGTGGACAACATCGCCCTGT-3') and primers for Bcl-2 (forward, 5'-CCTGGTGGACAACATCGCCCTGT-3'; reverse, 5'-GCCGGTTCAGGTACTCAGTCAT-3') were designed using the Primer Express 2.0 version. The probes were labeled at the 5' end with 6-carboxyfluorescein and at the 3' end with 6-carboxytetramethylrhodamine. Ribosomal RNA (18 S rRNA) from the Pre-developed TaqMan Assay Reagents (P/N, 4310893E) was used as endogenous control.
Statistical Analysis—For analysis of apoptosis, m, MTT, viability, and real time quantitative RT-PCR, values represent the means ± S.D. for at least three separate experiments performed in triplicate. The significance of differences between experimental variables was determined by using the Student's t test.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
Bcr/Abl-independent Imatinib Resistance Is Associated with Marked Activation of Lyn and Increased Expression of Bcl-2— Expression of phosphorylated Bcr/Abl and related proteins in resistant cells was examined next. As shown in Fig. 2A, levels of phospho-Bcr/Abl (activated) were dramatically reduced in K562-R and LAMA-R compared with their parental counterparts. Furthermore, consistent with earlier results involving K562 cells (21), phosphorylation of the Src kinase Lyn was markedly increased in both resistant cell lines. Levels of total Lyn were also increased in both resistant cell lines. However, in striking contrast to the reduction in Bcl-xL expression exhibited by K562-R and LAMA-R cells (Fig. 1C), Bcl-2 expression, basal levels of which were very low in parental K562 and LAMA84 cells, was dramatically increased in the resistant cell lines (Fig. 2A). In separate studies, no marked changes in the expression of other apoptotic regulatory proteins (e.g. Mcl-1, survivin, and XIAP) could be detected in resistant cells (data not shown). Thus, acquisition of the Bcr/Abl-independent, Lyn-activated phenotype was associated with down-regulation of Bcl-xL but with a pronounced increase in the basal levels of Bcl-2 expression.
|
Imatinib Mesylate Does Not Diminish Lyn Activation or Bcl-2 Expression and Fails to Induce Mitochondrial Dysfunction in LAMA-R Cells—The impact of imatinib mesylate on the expression/activation of Lyn and on the disposition of mitochondrial apoptotic regulatory proteins was examined next. As shown in Fig. 3A, exposure to imatinib mesylate did not modify the marked increase in levels of total and phospho-Lyn characteristic of LAMA-R cells. LAMA-R cells also displayed an increase in levels of the phosphorylated form of the Src kinase Hck compared with parental cells. However, in contrast to the case of Lyn, expression of phospho-Hck was diminished in both sensitive and resistant cells following imatinib mesylate exposure. In addition, imatinib mesylate also reduced expression of the phosphorylated form of the docking protein CrkL in imatinib mesylate-sensitive and -resistant cells.
|
m compared with wild type cells (Fig. 3C). Inhibition of Lyn Promotes Apoptosis and Down-regulates Bcl-2 in LAMA-R Cells—To investigate the functional relationship between enhanced Lyn activation and increased Bcl-2 expression, the Src kinase inhibitor PP2 was employed (31). Consistent with earlier results involving imatinib-resistant K562 cells displaying diminished Bcr/Abl expression (21), imatinib-resistant, Bcr/Abl-independent LAMA-R cells were more susceptible to apoptosis induced by 10 µM PP2 than their parental counterparts (Fig. 4A; 68.0 versus 35.5%; p < 0.05). In contrast, exposure to the inactive derivative PP3 did not trigger cell death in either sensitive or resistant cells. As shown by the Western blot analysis in Fig. 4B, PP2 markedly reduced levels of phospho-Bcr/Abl in wild type LAMA84 cells and phospho-Lyn in Bcr/Abl-independent LAMA-R cells. PP2 modestly reduced total Bcr/Abl expression but had no effect on levels of total Lyn. Significantly, exposure of LAMA-R cells to 10 µM PP2 reduced Bcl-2 mRNA levels by >60% (p < 0.001 compared with untreated cells), accompanied by a reduction in Bcl-2 protein expression (Fig. 4C). Together, these findings suggest that activation of the Lyn kinase in Bcr/Abl-independent, imatinib-resistant LAMA84 cells plays a functional role in enhanced Bcl-2 expression.
|
Parallel studies were carried out in K562 and LAMA84 cells stably transfected with the constitutively active (Y508F) or kinase-dead (K257D) Lyn constructs. Both transfected cells lines exhibited a marked increase in Lyn expression (Fig. 5A). On the other hand, expression of the Bcr/Abl protein was similar in parental and transfected cell lines. However, whereas Y508F-transfected K562 and LAMA84 cells displayed a pronounced increase in Bcl-2 protein levels, K275D-transfected cells did not. In contrast to alterations in Bcl-2 expression, no changes in levels of Bcl-xL were noted. Furthermore, stable transfection with constitutively active Lyn (Y508F) significantly protected K562 and LAMA84 cells from mitochondrial dysfunction (loss of m; data not shown) and apoptosis (Fig. 5, B and C) induced by 0.5 µM imatinib mesylate (p < 0.02 in each cell line), whereas the kinase-dead mutant did not. Together, these findings argue strongly that Lyn activation plays a significant functional role in enhanced Bcl-2 expression, and raise the possibility that these events contribute to imatinib mesylate resistance.
|
m (data not shown) or apoptosis in K562 and LAMA84 cells transfected with empty vector and kinase-defective Lyn (K275D), but strikingly increased imatinib mesylate-mediated lethality in constitutively active Lyn (Y508F)-transfected cells displaying increased expression of Bcl-2. Such findings provide indirect evidence that increased Bcl-2 expression in Lyn-activated cells may contribute to imatinib mesylate resistance. Imatinib Mesylate Down-regulates Phospho-Bcr/Abl, Bcl-xL, and XIAP Expression in Lyn-activated K562 Cells but Does Not Modify Levels of Phospho-Lyn and Bcl-2—Comparisons were then made between the effects of imatinib mesylate on the expression of various signaling and apoptotic regulatory proteins in K562 cells stably transfected with either constitutively active (Y508F) or inactive (K275D) Lyn (Fig. 5D). Whereas imatinib mesylate diminished expression of phospho-Bcr/Abl in all cell lines, in none of the cell lines did it modify expression of phospho-Lyn. Furthermore, imatinib mesylate failed to alter the pronounced increase in Bcl-2 expression in Lyn-activated cells (Y508F). In contrast, imatinib mesylate induced clear reductions in expression of Bcl-xL and XIAP in each of the cell lines. Finally, imatinib mesylate-mediated PARP degradation was attenuated in Y508F-transfected cells compared with cells transfected with both empty vector and the K275D mutant. The failure of imatinib mesylate to diminish increased expression of Bcl-2 in Lyn-activated cells is consistent with a role for this protein in the development of imatinib mesylate resistance.
Enforced Expression of Bcl-2 Protects CML Cells from Imatinib Mesylate- and PP2-mediated Lethality—The preceding studies provided indirect evidence that alterations in expression of Bcl-2 might contribute to imatinib mesylate resistance in Lyn-activated cells. To test this hypothesis more directly, LAMA84 and K562 cells were transiently transfected with cDNA constructs encoding the wild type Bcl-2 protein, and resulting effects on the response of cells to imatinib mesylate and the Src kinase inhibitor PP2 were monitored. As shown by the Western blots in Fig. 6A (left panels), K562 and LAMA84 cells transfected with the Bcl-2 cDNA displayed marked increases in Bcl-2 protein levels but no changes in expression of phospho-Lyn. Furthermore, Bcl-2 transfectants of both LAMA84 and K562 were significantly more resistant to the lethal effects of imatinib mesylate (1 µM) than their control counterparts, p < 0.05 and 0.01 (Fig. 6A, right panel), respectively. LAMA84 and K562 cells ectopically expressing Bcl-2 were also significantly less sensitive to the lethal effects of PP2, which was shown previously to down-regulate Bcl-2 expression in wild type cells (Fig. 4C), compared with their control counterparts (Fig. 6A, right panel). These findings provide support for the notion that increased Bcl-2 expression in Lyn-activated K562 and LAMA84 cells contributes functionally to imatinib mesylate resistance.
|
The Small Molecule Bcl-2 Inhibitor HA14-1 Is More Lethal to LAMA-R Than to Parental Cells and Sensitizes LAMA-R Cells to Imatinib Mesylate-mediated Lethality—The preceding findings (Fig. 5, B and C) demonstrated that treatment with the small molecule Bcl-2 inhibitor HA14-1 sensitized parental K562 or LAMA84 cells transiently transfected with cDNA encoding constitutively active (but not kinase-defective) Lyn to imatinib mesylate lethality. Attempts were then undertaken to determine whether a similar phenomenon occurred in imatinib mesylate-resistant CML cells displaying increased Lyn activation in conjunction with diminished Bcr/Abl expression (Fig. 2A). As shown by the dose-response curves in Fig. 7A, LAMA-R and K562-R cells were significantly more sensitive than their parental counterparts to the growth inhibitory effects of various concentrations of HA14-1, as determined by the MTT assay. LAMA-R and K562-R cells were also significantly more susceptible to HA14-1-mediated apoptosis than parental controls (Fig. 7B).
|
Co-administration of Imatinib Mesylate and HA14-1 in LAMA-R Cells Results in the Pronounced Release of Cytochrome c and AIF into the Cytosol Accompanied by Mitochondrial Translocation of Bax—The effects of HA14-1 on imatinib mesylate-mediated mitochondrial events in LAMA-R cells were examined next. Consistent with the previous results shown in Fig. 3B, exposure of LAMA-R cells to 0.5 or 1 µM imatinib mesylate alone had no effect on the intracellular disposition of Bax, which resided primarily in the cytosol, or on cytochrome c and AIF, which were primarily localized to the mitochondrial fraction (data not shown). Similarly, 10 µM HA14-1 alone exerted very modest effects on Bax translocation or cytochrome c/AIF redistribution (Fig. 7E). However, when the agents were combined, Bax underwent a pronounced redistribution from the cytoplasm to the mitochondria, a phenomenon characteristically associated with apoptosis (39). This event was accompanied by the reciprocal translocation of cytochrome c and AIF from the mitochondria to the cytosol. Combined treatment was also associated with the faint appearance of a Bcl-2 cleavage product, particularly in the mitochondrial fractions (Fig. 7E). These findings suggest that disruption of Bcl-2 function by HA14-1 in LAMA-R cells restores, at least in part, the capacity of imatinib mesylate to induce mitochondrial dysfunction and redistribution of pro-apoptotic Bcl-2 family members in otherwise imatinib mesylate-resistant cells.
Inhibition or Down-regulation of Bcl-2 Increases the Sensitivity of LAMA-R Cells to the Topoisomerase II Inhibitor VP-16—To determine whether increased expression of Bcl-2 in Lyn-activated cells might also play a role in determining the sensitivity of imatinib mesylate-resistant cells to other cytotoxic agents, cells were exposed to the topoisomerase inhibitor VP-16 following transient transfection with Bcl-2 siRNA or Bcl-2 antisense oligonucleotides as described for results displayed in Fig. 6, B and C. As shown in Fig. 8A, the loss of cell viability induced by VP-16 (5 µM, 24 h) was significantly greater in LAMA-R cells transfected with Bcl-2 siRNA or Bcl-2 antisense oligonucleotides compared with those transfected with controls (p < 0.01 in each case). Similar results were obtained in K562-R cells (data not shown). Parallel studies involving the small molecule Bcl-2 inhibitor HA14-1 were performed in parental LAMA84 and LAMA-R cells (Fig. 8B). Coadministration of HA14-1 (10 µM) with varying concentrations of VP-16 resulted in a dramatic increase in apoptosis in LAMA-R cells, but exerted minimal effects in parental LAMA84 controls, which express very low basal levels of Bcl-2 (Fig. 2A). Most interesting, LAMA-R cells were somewhat more susceptible to the lethal actions of VP-16 alone compared with parental cells, presumably reflecting loss of the protective effects of Bcr/Abl and/or Bcl-xL (40). Parallel results were obtained when loss of m was monitored (data not shown).
|
m) in LAMA-R cells but exerted no effect in the parental line (Fig. 8D). A control peptide (cpm-1285mt) was without effect. Taken together with the preceding results, these findings suggest that increased expression of Bcl-2 in Bcr/Abl-diminished, Lyn-activated CML cells plays a significant functional role in protecting cells from mitochondrial dysfunction and apoptosis resulting from various environmental stresses, including exposure to cytotoxic agents such as imatinib mesylate and VP-16. |
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Although a relationship between Lyn and Bcr/Abl in the pathogenesis of CML is supported by several lines of evidence (27, 28), genetic and biochemical studies suggest that Lyn may exert either pro- or anti-apoptotic functions, depending on cell context. For example, genotoxic stimuli (e.g. ionizing radiation and ara-C) activate the Lyn kinase, leading to induction of cell death through the Lyn-dependent activation of stress-activated protein kinase/c-Jun N-terminal kinase (26, 42). On the other hand, Lyn has been shown to play a key role in the transduction of anti-apoptotic signals initiated by growth factors and cytokines, at least in vitro (43, 44). In support of this model, Lyn negatively regulates the proapoptotic function of GADD34 in HEK293 and HeLa cells undergoing apoptosis in response to DNA damage (29). Furthermore, Lyn and Fgr protein kinases block retinoic acid-induced apoptosis and promote granulocytic differentiation in HL-60 cells (45). In a BCR/ABL-transfected murine myeloid cell line, p53/p56lyn displayed a marked increase in activity compared with parental cells; moreover, p53/p56lyn kinase activity is significantly higher in Bcr/Abl-positive myeloid cell lines (e.g. K562, BV173, and LAMA84) than in Bcr/Abl-negative myeloid cell lines such as JOSK-M (27). Furthermore, phosphorylation of Bcr/Abl was associated with Lyn activation in BCR/ABL-transfected HL-60 cells (28). Finally, in CML cells, Lyn may mediate pathological cross-talk between Bcr/Abl and CXCR4, a G protein-coupled receptor of the stromally derived factor pathway, thereby disrupting chemokine signaling and chemotaxis (28). Collectively, these findings suggest that in hematopoietic cells, Lyn represents an important downstream target of Bcr/Abl and raise the possibility Lyn may include some of the anti-apoptotic functions of this oncoprotein.
The results described here indicate, for the first time, that Lyn activation plays a functional role in Bcl-2 up-regulation exhibited by cells displaying Bcr/Abl-independent forms of imatinib mesylate resistance. In the study by Nimminapalli et al. (20), loss of Bcr/Abl in K562 cells was associated with down-regulation of STAT5 as well as with reduced expression of Bcl-xL, consistent with our results in K562-R and LAMA-R cells. In contrast to the down-regulation of these proteins, K562 exhibiting diminished expression of Bcr/Abl displayed increased expression of Bcl-2 (20). However, the activation status of Lyn was not specifically examined in this study. In the report by Donato et al. (21), Lyn activation in imatinib mesylate-resistant Bcr/Abl-independent K562 cells as well as patient-derived cells was also associated with down-regulation of STAT5, but Bcl-2 expression was not examined. In the present study, several lines of evidence argue strongly for a causal relationship between Lyn activation and up-regulation of Bcl-2. First, LAMA-R cells exhibiting a pronounced activation of Lyn displayed a dramatic increase in levels of Bcl-2 mRNA and protein. Second, transient transfection of wild type LAMA84 cells or stable transfection of wild type K562 and LAMA84 cells with a constitutively active (but not a kinase-defective) Lyn construct resulted in an increase in Bcl-2 protein. Third, exposure of LAMA-R cells to the Src kinase inhibitor PP2 down-regulated Bcl-2 mRNA and protein expression. Collectively, these findings are consistent with the notion that Lyn activation plays a significant functional role in Bcl-2 up-regulation in these cells. In this context, evidence of increased Bcl-2 promoter activity or diminished ubiquitination of Bcl-2 was not observed in v-Cbl-transfected 32Dcl3 exhibiting enhanced basal Lyn activation and increased Bcl-2 expression compared with control cells (38). The mechanism by which Lyn activation increases Bcl-2 expression in K562-R and LAMA-R cells displaying reduced Bcr/Abl expression is presently unknown, and to the best of our knowledge, this association has not been reported previously. However, results of the RT-PCR studies suggest that Lyn-mediated up-regulation of Bcl-2 may occur at the transcriptional level. The possibility exists that activation of Lyn, a Src family tyrosine kinase, may act directly or indirectly (for example, through downstream signaling pathways) to activate certain transcription factors (e.g. NF-
B, Myb, C/EBP, cAMP-response element-binding protein) known to be major transcriptional regulators of Bcl-2 (46–49). Attempts to explore the mechanistic link between Lyn activation and Bcl-2 expression are currently underway.
It is noteworthy that Bcl-2 has been shown to cooperate with Bcr/Abl to promote leukemogenesis and to result in a more aggressive tumor phenotype (50, 51). Although increased Bcl-2 expression has been observed in imatinib-resistant K562 cells displaying loss of Bcr/Abl (20), the functional role of this phenomenon has not been investigated. The present results suggest that increased Bcl-2 expression in Lyn-activated leukemia cells helps to protect them from various environmental stresses, particularly under conditions in which the cytoprotective functions of Bcr/Abl are lost. Significantly, HA14-1, a small molecule Bcl-2 inhibitor, was primarily effective in reducing cell viability in the LAMA-R cell line, indicating that Bcl-2 plays an important role in cell survival in this setting. In contrast, HA14-1 had relatively little impact on the survival of parental Bcr/Abl-positive cells, which express very low to absent levels of Bcl-2. One possibility is that increased expression of Bcl-2 in Lyn-activated cells displaying reduced expression of Bcr/Abl compensates for the down-regulation or inactivation of survival factors (e.g. Bcl-xL, STAT5, Akt, and mitogen-activated protein kinase) that accompanies loss of Bcr/Abl (20, 21).
Several lines of evidence suggest that increased Bcl-2 expression in Lyn-activated, Bcr/Abl-diminished CML cells contributes to the imatinib mesylate-resistant phenotype. First, the ability of HA14-1 to promote imatinib mesylate lethality in LAMA-R cells suggests, albeit indirectly, a functional role for Bcl-2 in drug resistance. Second, down-regulation of Bcl-2 expression by either RNA interference or antisense strategies restored the ability of imatinib mesylate to trigger cell death in otherwise resistant cells. Third, transient transfection of K562 and LAMA84 cells with cDNA encoding Bcl-2 significantly protected them from imatinib mesylate-mediated lethality. Such findings are consistent with recent reports (52) suggesting that strategies that interfere with Bcl-2 function (e.g. antisense approaches) may enhance the lethal effects of imatinib mesylate in Bcr/Abl+ leukemia cells. The mechanism by which imatinib mesylate exerts its lethal effects toward leukemia cells exhibiting diminished Bcr/Abl expression remains to be determined, although it may be relevant that in such cells residual Bcr/Abl kinase activity has been detected (21). An alternative possibility is that increased Bcl-2 expression may protect against the lethal consequences of inhibition of other kinases by imatinib mesylate (53). Whatever the mechanism, the present findings suggest that strategies targeting Bcl-2 may be effective in overcoming certain forms of imatinib mesylate resistance associated with Lyn activation and Bcl-2 up-regulation.
It is also noteworthy that co-administration of minimally toxic concentrations of HA14-1 dramatically enhanced the lethality of an agent other than imatinib mesylate (e.g. the topoisomerase inhibitor VP-16) to trigger mitochondrial dysfunction and apoptosis in LAMA-R cells. Similar results were noted with Bcl-2 siRNA and antisense strategies. Specifically, HA14-1 promoted VP-16-mediated translocation of Bax to the mitochondria and release of cytochrome c and AIF into the cytoplasm of LAMA-R cells, whereas VP-16 administered alone was largely ineffective. Furthermore, comparable results were obtained when a Bcl-2-binding peptide (cpm-1285) was employed. This peptide was designed by chemically attaching a fatty acid to a peptide derived from the proapoptotic protein Bad, allowing the compound to enter cells and bind Bcl-2 (34). Although the mechanism by which Bcl-2 blocks apoptosis remains the subject of debate, interference with the ability of BH3 domain-only molecules (e.g. Bid, Bad, Bim, and Noxa) to activate multidomain proapoptotic members (e.g. Bax and Bak), thereby preventing the release of pro-apoptotic proteins (e.g. cytochrome c, Smac/Diablo, and AIF), represents a leading candidate (54). It has been reported that HA14-1 binds to the Bcl-2 BH3 domain, thereby disrupting interactions with proapoptotic proteins such as Bax and Bak (32). Together, these findings support the concept that up-regulation of Bcl-2 in Bcr/Abl-down-regulated, Lyn-activated leukemia cells may act in a more general manner to promote cell survival in the face of environmental stresses, including DNA-damaging agents.
The observation that Bcr/Abl-independent, Lyn-activated forms of imatinib mesylate resistance are associated with up-regulation of Bcl-2 has potential implications for the rational design of targeted strategies in certain forms of drug-resistant CML. Clinical experience to date suggests that imatinib mesylate resistance is most frequently related to Bcr/Abl mutations (e.g. 70%) and less often to gene amplification and/or increased protein expression (17). Although sporadic cases have been reported (22), the frequency with which Bcr/Abl-independent, Lyn-activated forms of imatinib mesylate resistance occurs in patients is not known at this time. In any case, resistant cells expressing mutant Bcr/Abl protein may retain their sensitivity to kinase inhibitors (e.g. PD166326, PD180970, and CGP76030 other than imatinib mesylate (21, 56, 57). Alternatively, resistant cells in which Bcr/Abl expression is increased may be vulnerable to a strategy combining imatinib mesylate with other novel agents such as histone deacetylase inhibitors (e.g. SAHA (58) or LAQ824 (59)). On the other hand, a rational strategy directed against Lyn-activated cells displaying reduced expression of Bcr/Abl might require specific inhibitors of Lyn (21) or, alternatively, agents capable of circumventing Bcl-2 resistance. These include CDK inhibitors (e.g. Flavopiridol, which has been reported to act independently of Bcl-2 (60), as well as Bcl-2 antisense oligonucleotides, which diminish Bcl-2 levels (52, 55)). In particular, approaches capable of disrupting Bcl-2 function or reducing Bcl-2 expression may be effective in potentiating the response of such resistant cells to both imatinib mesylate as well as more conventional antileukemic agents (e.g. VP-16). Accordingly, attempts to explore the latter strategies in CML cells displaying Bcr/Abl-independent forms of imatinib mesylate resistance are currently underway.
|
FOOTNOTES |
|---|
To whom correspondence should be addressed: Division of Hematology/Oncology, MCV Station Box 230, Virginia Commonwealth University/Medical College of Virginia, Richmond, VA 23298. Tel.: 804-828-5211; Fax: 804-828-8079; E-mail: stgrant{at}hsc.vcu.edu.
1 The abbreviations used are: CML, chronic myelogenous leukemia; RT, reverse transcriptase; FITC, fluorescein isothiocyanate; PI, propidium iodide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; HA, hemagglutinin; PARP, poly [ADP-ribose] polymerase; bcr, breakpoint cluster region; siRNA, small interfering RNA; dsRNAi, double-stranded RNA interference; DiOC6, 3,3-dihexyloxacarbocyanine; PP2, 4-amino-5-[4-chlorophenyl]-7-[t-butyl]pyrazolo[3,4-d]pyrimidine; PP3, 4-amino-7-phenylpyrazolo[3,4-d]pyrimidine; AIF, apoptosis-inducing factor.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
